SICHUAN KELUN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.95 CNY | +3.41% |
|
+4.78% | +16.87% |
| Sales 2024 * | 23.19B 3.2B 267B | Sales 2025 * | 25.16B 3.48B 290B | Capitalization | 54.01B 7.46B 622B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.85B 394M 32.85B | Net income 2025 * | 3.07B 424M 35.41B | EV / Sales 2024 * | 2.39 x |
| Net Debt 2024 * | 1.35B 187M 15.58B | Net Debt 2025 * | 1.08B 149M 12.45B | EV / Sales 2025 * | 2.19 x |
| P/E ratio 2024 * |
18.7
x | P/E ratio 2025 * |
17.1
x | Employees | 19,798 |
| Yield 2024 * |
1.27% | Yield 2025 * |
1.99% | Free-Float | 66.94% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.41% | ||
| 1 week | +4.78% | ||
| 1 month | +13.09% | ||
| 3 months | +49.63% | ||
| 6 months | +26.02% | ||
| Current year | +16.87% |
1 week
32.19
34.64
1 month
28.8934.64
Current year
21.6034.64
1 year
21.6034.64
3 years
14.5334.64
5 years
14.5334.64
10 years
12.2636.07
| Managers | Title | Age | Since |
|---|---|---|---|
Si Chuan Liu
CEO | Chief Executive Officer | 40 | 26/09/26 |
Ge Xin Liu
FOU | Founder | 73 | 01/96/01 |
De Gui Lai
DFI | Director of Finance/CFO | 52 | 01/01/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ge Xin Liu
FOU | Founder | 73 | 01/96/01 |
Guang Ji Wang
BRD | Director/Board Member | 71 | 01/18/01 |
Yun Pei Guo
BRD | Director/Board Member | 76 | 22/16/22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.95% | 4 M€ | -2.96% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 33.95 | +3.41% | 23,105,040 |
| 29/24/29 | 32.83 | +1.33% | 19,853,890 |
| 26/24/26 | 32.4 | +3.51% | 22,729,680 |
| 25/24/25 | 31.3 | +4.13% | 28,967,370 |
End-of-day quote Shenzhen S.E., April 30, 2024
More quotes
Sichuan Kelun Pharmaceutical Co., Ltd. specializes in developing, manufacturing and marketing pharmaceuticals. Net sales break down by activity as follows:
- manufacturing and sale of pharmaceutical products (98%). Net sales break down by family of products between injectable drugs (56.9%) and other (43.1%; tablets, capsules, granules, etc.);
- other (2%).
China accounts for 94.6% of net sales.
Sector
Pharmaceuticals
Calendar
15/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
33.95
CNY
Average target price
41.04
CNY
Spread / Average Target
+20.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.87% | 7.46B | |
| +26.08% | 662B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| -3.40% | 157B |
- Stock Market
- Equities
- 002422 Stock
